一种新的药物组合克服了对复发儿童癌症的抗药性,在动物身上显示出希望。 A new drug combo overcomes resistance in relapsed childhood cancer, showing promise in animals.

澳大利亚研究人员发现, 经批准用于淋巴瘤的药物罗米德素与常规化疗相结合, 可以克服神经母细胞瘤复发的抗治疗性, 这是一种致命的儿童癌症. Australian researchers have found that combining romidepsin, a drug approved for lymphoma, with standard chemotherapy can overcome treatment resistance in relapsed neuroblastoma, a deadly childhood cancer. 这种方法绕过了JNK途径,这条途径经常在复发肿瘤中失效,引发癌症细胞死亡,并阻止动物模型肿瘤生长。 The approach bypasses the JNK pathway, which often fails in recurrent tumors, triggering cancer cell death and halting tumor growth in animal models. 发表在《科学进步》上的调查结果表明,这种结合可以改善生存,降低化疗剂量,减少副作用。 The findings, published in Science Advances, suggest the combination may improve survival and allow lower chemotherapy doses, reducing side effects. 虽然前景看好,但在病人使用治疗之前需要人类临床试验。 While promising, human clinical trials are needed before the treatment can be used in patients.